Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Aug 13, 2024
Received NMPA approval of avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia, expanding rare disease product lines
Received IND approval from NMPA to evaluate F230 for the treatment of pulmonary arterial hypertension
Read more at globenewswire.comNASDAQ:GYRE (2/25/2025, 8:00:01 PM)
11.44
+0.89 (+8.44%)
Find more stocks in the Stock Screener
